Metabolic Syndrome in People Living with Human Immunodeficiency Virus: An Assessment of the Prevalence and the Agreement between Diagnostic Criteria
Table 3
Prevalence (95% confidence interval) of the metabolic syndrome by the JIS, IDF, and ATPIII 2005 criteria presented by gender and HIV-related subgroups.
Subgroups
JIS
value
IDF
value
ATPIII 2005
value
Gender ()
Overall
28.2 (25.0–31.4)
<0.001
26.5 (23.3–29.6)
<0.001
24.1 (21.0–27.1)
<0.001
Men
16.6 (10.8–22.4)
11.5 (6.5–16.5)
13.4 (8.1–18.7)
Women
31.3 (27.6–35.0)
30.5 (26.8–34.2)
26.9 (23.3–30.5)
HIV duration ()
Overall
27.8 (24.6–31.1)
0.002
26.1 (22.9–29.2)
0.003
23.7 (20.6–26.7)
0.001
yrs
22.5 (18.1–26.9)
21.0 (16.8–25.3)
17.9 (13.8–21.9)
yrs
32.6 (27.9–37.2)
30.5 (26.0–35.1)
28.8 (24.3–33.2)
CD4 count ()
Overall
29 (24.4–33.6)
0.118
28.4 (23.8–33)
0.115
25.2 (20.8–29.6)
0.060
CD4
25.3 (19.0–31.5)
24.7 (18.5–30.9)
21.0 (15.1–26.8)
CD4
32.6 (25.9–39.3)
32.1 (25.4–38.8)
29.4 (22.9–35.9)
ART use ()
Overall
28.0 (24.7–31.4)
0.292
26.2 (22.9–29.4)
0.305
24.3 (21.1–27.5)
0.175
No ART
34.8 (21.0–48.6)
32.6 (19.1–46.2)
32.6 (19.1–46.2)
On ART
27.6 (24.1–31.0)
25.7 (22.4–29.1)
23.7 (20.5–27.0)
ART regimens
0.017
0.031
0.039
1st line
23.9 (19.9–28.0)
22.5 (18.6–26.5)
20.7 (16.8–24.5)
2nd line
32.9 (22.5–43.3)
29.1 (19.1–39.1)
30.4 (20.2–40.5)
Others
35.1 (27.4–42.8)
33.1 (25.5–40.7)
29.1 (21.7–36.4)
Data are percentage and 95% confidence intervals; ATPIII: Adult Treatment Panel III; EGIR: European Group for the Study of Insulin Resistance; IDF: International Diabetes Federation; JIS: Joint Interim Statement; HIV: human immunodeficiency virus; ART: antiretroviral therapy. Data were missing for some characteristics. For each grouping variable for which data were missing for some participants, the number of participants with valid data is provided (attached to the name of the variable), as well as the overall prevalence of metabolic syndrome in that subsample.